Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial

Table 1

General data of the CRC patients in adjuvant/palliative chemotherapy (FOLFOX4) without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).

Parameters		C group; 𝑛=23	UT group; 𝑛=20
^aStates T	T1	0	1
	T2	1	1
	T3	16	12
	T4	6	6
^aStates N	N0	1	2
	N1	8	8
	N2	11	10
^aStates M	M0	13	17
	M1	10	3
Age	<50	4	2
	51–65	10	12
	66–80	9	6
Gender	Female	16	10
	Male	7	10
Smoke	Smokers	2	0
	ex-smokers	8	10
	no smokers	13	10
Associated chronic diseases	Without	5	4
	Hypertension	6	6
	Hypertension + coronary diseases/dyslipidemia/diabetes	3	7
	Diabetes	2	2
	Others	4	1

^aStage of disease currently described by TNM, as published by the American Joint Committee on Cancer (AJCC) and American Cancer Society (ACS).